Filtered By:
Specialty: Urology & Nephrology
Cancer: Hepatocellular Carcinoma
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
CONCLUSION: Greater frequency and higher grades of irAEs are associated with better treatment response in patients with RCC and urothelial malignancy receiving ICI therapy. The presence of liver metastases denotes a negative predictive marker for immunotherapy efficacy.
SUMMARY: Immune checkpoint inhibitors (ICI) are increasingly used to treat genitourinary (GU) malignancies. However, clinical data regarding patients with advanced-stage GU malignancies treated with ICI is lacking. Thus, we performed a single-center, retrospective cohort study on patients with metastatic and unresectable renal cell carcinoma (RCC) and ...
Source: Urologic Oncology - January 22, 2021 Category: Urology & Nephrology Authors: Ma VT, Su CT, Hu M, Taylor JMG, Daignault-Newton S, Kellezi O, Dahl MN, Shah MA, Erickson S, Lora J, Hamasha R, Ali A, Yancey S, Kiros L, Balicki HM, Winfield DC, Green MD, Alva AS Tags: Urol Oncol Source Type: research
